Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05687266 · ClinicalTrials.gov registry record · Phase 3

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

A Phase 3 study of NSCLC, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
1,350
Enrollment target
20
Study locations

NCT05687266 is a Phase 3 study of NSCLC that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 1,350 participants, above the 205-participant average among 71 other NSCLC trials with a reported enrollment target (559% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05687266, a Phase 3 study of NSCLC, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,350 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).

Conditions Studied

NSCLC

Interventions

  • DRUG Pembrolizumab
  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Durvalumab
  • DRUG Datopotamab deruxtecan

Study Locations (20)

Florida

  • Research Site - Fort Myers
  • Research Site - Jacksonville
  • Research Site - St. Petersburg
  • Research Site - West Palm Beach

Arkansas

  • Research Site - Hot Springs
  • Research Site - Little Rock
  • Research Site - Springdale

California

  • Research Site - Fountain Valley
  • Research Site - Los Angeles
  • Research Site - Orange

Iowa

  • Research Site - Bettendorf
  • Research Site - Iowa City
  • Research Site - Waukee

Arizona

  • Research Site - Phoenix
  • Research Site - Tucson

Louisiana

  • Research Site - Baton Rouge
  • Research Site - Covington

Colorado

  • Research Site - Boulder

Illinois

  • Research Site - Hinsdale

Trial Details

FieldValue
Enrollment Target 1,350 participants
Start Date 2022-12-29
Est. Completion 2027-11-01
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05687266

The ClinicalTrials.gov registry entry for NCT05687266 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,350 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 205-participant average among 71 other NSCLC trials with a reported enrollment target (559% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with NSCLC appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT05687266 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, Arkansas, California.

Frequently Asked Questions

What is clinical trial NCT05687266 about?

NCT05687266 is a clinical study titled "Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations". This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line t...

What is the current status of trial NCT05687266?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,350 participants. The study started on 2022-12-29. Estimated completion is 2027-11-01.

What conditions does trial NCT05687266 study?

This clinical trial studies the following conditions: NSCLC.

What interventions are being tested in trial NCT05687266?

The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), Durvalumab (DRUG), Datopotamab deruxtecan (DRUG).

Who is sponsoring clinical trial NCT05687266?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05687266 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for NSCLC

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

NSCLC

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.